161 related articles for article (PubMed ID: 11284756)
1. The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss.
Hardus P; Verduin WM; Berendschot TT; Kamermans M; Postma G; Stilma JS; van Veelen CW
Acta Ophthalmol Scand; 2001 Apr; 79(2):169-74. PubMed ID: 11284756
[TBL] [Abstract][Full Text] [Related]
2. Vigabatrin: longterm follow-up of electrophysiology and visual field examinations.
Hardus P; Verduin W; Berendschot T; Postma G; Stilma J; van Veelen C
Acta Ophthalmol Scand; 2003 Oct; 81(5):459-65. PubMed ID: 14510792
[TBL] [Abstract][Full Text] [Related]
3. Visual field and electrophysiological abnormalities due to vigabatrin.
van der Torren K; Graniewski-Wijnands HS; Polak BC
Doc Ophthalmol; 2002 Mar; 104(2):181-8. PubMed ID: 11999625
[TBL] [Abstract][Full Text] [Related]
4. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.
Harding GF; Wild JM; Robertson KA; Lawden MC; Betts TA; Barber C; Barnes PM
Epilepsia; 2000 Nov; 41(11):1420-31. PubMed ID: 11077455
[TBL] [Abstract][Full Text] [Related]
5. Vigabatrin effect on inner retinal function.
Coupland SG; Zackon DH; Leonard BC; Ross TM
Ophthalmology; 2001 Aug; 108(8):1493-6; discussion 1497-8. PubMed ID: 11470707
[TBL] [Abstract][Full Text] [Related]
6. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication.
Hardus P; Verduin WM; Postma G; Stilma JS; Berendschot TT; van Veelen CW
Epilepsia; 2000 May; 41(5):581-7. PubMed ID: 10802764
[TBL] [Abstract][Full Text] [Related]
7. Electro-ophthalmological recovery after withdrawal from vigabatrin.
Graniewski-Wijnands HS; van der Torren K
Doc Ophthalmol; 2002 Mar; 104(2):189-94. PubMed ID: 11999626
[TBL] [Abstract][Full Text] [Related]
8. Visual field defects associated with vigabatrin therapy.
Lawden MC; Eke T; Degg C; Harding GF; Wild JM
J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):716-22. PubMed ID: 10567485
[TBL] [Abstract][Full Text] [Related]
9. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss.
Harding GF; Wild JM; Robertson KA; Rietbrock S; Martinez C
Neurology; 2000 Aug; 55(3):347-52. PubMed ID: 10932265
[TBL] [Abstract][Full Text] [Related]
10. The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.
Comaish IF; Gorman C; Brimlow GM; Barber C; Orr GM; Galloway NR
Doc Ophthalmol; 2002 Mar; 104(2):195-212. PubMed ID: 11999627
[TBL] [Abstract][Full Text] [Related]
11. Vigabatrin; its effect on the electrophysiology of vision.
Harding GF; Robertson K; Spencer EL; Holliday I
Doc Ophthalmol; 2002 Mar; 104(2):213-29. PubMed ID: 11999628
[TBL] [Abstract][Full Text] [Related]
12. Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
Kjellström U; Lövestam-Adrian M; Andréasson S; Ponjavic V
Doc Ophthalmol; 2008 Sep; 117(2):93-101. PubMed ID: 18188629
[TBL] [Abstract][Full Text] [Related]
13. Visual electrophysiological effect of a GABA transaminase blocker.
Harding GF; Robertson KA; Edson AS; Barnes P; Wild J
Doc Ophthalmol; 1998-1999; 97(2):179-88. PubMed ID: 10765970
[TBL] [Abstract][Full Text] [Related]
14. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.
Ponjavic V; Andréasson S
Doc Ophthalmol; 2001 Jan; 102(1):63-72. PubMed ID: 11475366
[TBL] [Abstract][Full Text] [Related]
15. Visual field constriction and electrophysiological changes associated with vigabatrin.
Besch D; Kurtenbach A; Apfelstedt-Sylla E; Sadowski B; Dennig D; Asenbauer C; Zrenner E; Schiefer U
Doc Ophthalmol; 2002 Mar; 104(2):151-70. PubMed ID: 11999623
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
Daneshvar H; Racette L; Coupland SG; Kertes PJ; Guberman A; Zackon D
Ophthalmology; 1999 Sep; 106(9):1792-8. PubMed ID: 10485552
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication.
Kjellström U; Andréasson S; Ponjavic V
Acta Ophthalmol; 2014 Mar; 92(2):149-57. PubMed ID: 23387307
[TBL] [Abstract][Full Text] [Related]
18. Visual function loss from vigabatrin: effect of stopping the drug.
Johnson MA; Krauss GL; Miller NR; Medura M; Paul SR
Neurology; 2000 Jul; 55(1):40-5. PubMed ID: 10891902
[TBL] [Abstract][Full Text] [Related]
19. Electroretinographic (ERG) responses in pediatric patients using vigabatrin.
Moskowitz A; Hansen RM; Eklund SE; Fulton AB
Doc Ophthalmol; 2012 Jun; 124(3):197-209. PubMed ID: 22426576
[TBL] [Abstract][Full Text] [Related]
20. Vigabatrin and retinal changes.
Jensen H; Sjö O; Uldall P; Gram L
Doc Ophthalmol; 2002 Mar; 104(2):171-80. PubMed ID: 11999624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]